Clinical Report: Misleading beta-glucan assay results during fungal sepsis management
Overview
This case study highlights the potential for false-positive results in the (1,3)-β-D-glucan assay due to contamination from medical sterile gauze. The findings emphasize the need for careful interpretation of G test results in the context of clinical improvement and microbiological evidence.
Background
The (1,3)-β-D-glucan (BDG) assay is a critical tool in diagnosing invasive fungal diseases (IFDs), particularly in immunocompromised patients. However, its susceptibility to false-positive results can complicate clinical decision-making. Understanding the sources of these false positives is essential for accurate diagnosis and effective management of fungal infections.
Data Highlights
Indicator
Result
WBC
↑
CRP
↑
PCT
↑
GM test
Not identified
G test
↑ for 3 months
Key Findings
The (1,3)-β-D-glucan assay can yield false-positive results due to contamination from medical sterile gauze.
In this case, a patient with fungal sepsis showed persistent positive G test results despite clinical improvement.
Blood cultures remained negative throughout the treatment, highlighting the importance of correlating G test results with clinical evidence.
Confounding factors such as antibiotics and bacterial infections were ruled out as causes for the elevated G test results.
Medical sterile gauze contains significant amounts of BDG, which can mislead clinicians in the diagnosis of IFDs.
Clinical Implications
Incorporate recommendations for routine checks for contamination sources in clinical settings.
Conclusion
This case underscores the need for careful evaluation of (1,3)-β-D-glucan assay results in the context of clinical improvement and microbiological evidence to avoid misdiagnosis and inappropriate antifungal treatment.
